Articles tagged with Cancer Patients
ASHG honors Drs. Weitzel and Blazer for their exceptional contributions to cancer genomics education, impacting thousands of patients globally. Their initiatives have prepared clinicians for leadership roles in translational research and improved healthcare outcomes.
A team at Fred Hutchinson Cancer Research Center has identified a gene called DUX4 that can prevent the immune system from recognizing and attacking cancer cells. This discovery suggests that blocking the activity of this gene might increase the success of immunotherapy treatments for a wide range of cancers.
Researchers discovered that leukemia stem cells suppress NKG2D-L proteins, evading the immune system. By inhibiting PARP1, these cells can be recognized and eliminated by NK cells.
Radiotherapy patients experiencing hurricane disasters had significantly worse overall survival rates than those completing treatment in normal circumstances. Longer disaster declarations were associated with increasingly worse survival outcomes.
Researchers discovered a cellular pathway linked to cancer that may benefit patients with hepatocellular carcinoma by reducing side effects and extending immunotherapy duration. The study found that blocking the IL-6/JAK1 pathway could resolve immunotherapy side effects and improve treatment outcomes.
Researchers have developed an AI algorithm that can analyze breast ultrasound images to detect cancer with high accuracy. The algorithm uses synthetic data to train itself, achieving nearly 100% classification rate on real-world images.
Researchers have identified an enzyme called LPCAT1 that plays a key role in tumor growth by changing the phospholipid composition of cancer cells' plasma membranes. When genetically depleted in mice, malignancies shrank dramatically, suggesting LPCAT1 as a potential new drug target for various cancer types.
The University of Colorado Cancer Center is enrolling patients in a Phase II clinical trial evaluating the effectiveness of Rucaparib, a PARP inhibitor, as maintenance therapy for endometrial cancer. The trial aims to determine the drug's ability to prevent cancer cell growth and death in patients with metastatic or recurrent disease.
Researchers have identified a new cell growth pathway that could lead to better treatments for metastatic cancers. The study found that the mEAK-7 gene is highly expressed in metastatic non-small cell lung cancer cells and plays a key role in cancer metastasis.
Researchers are testing a therapy called bermekimab, which blocks inflammation and pain-causing molecules in the immune system. The trial aims to improve outcomes in lung, pancreatic and ovarian cancer patients, with the goal of reducing symptoms such as weight loss and decreased mobility.
A worldwide coalition of researchers has agreed that light therapy is an effective intervention for preventing oral mucositis in head and neck cancer patients. The new guidelines recommend photobiomodulation therapy, a low-dose light therapy, to prevent the painful ulcers resulting from radiation therapy.
City of Hope scientists develop blood test to forecast breast cancer recurrence risk in patients with solid tumors. The innovative approach aims to personalize treatment strategies and improve patient outcomes.
A new probe has been developed to help surgeons detect cancer cells during surgery, with the potential to improve surgical outcomes for patients. The probe uses fluorescence imaging and has been published in Chemical Science, a study led by RCSI researchers.
A phase III trial found that a three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer. The treatment resulted in a median overall survival of 9 months compared to 5.4 months for standard therapy.
Researchers at Stanford University School of Medicine have developed a computer algorithm that integrates various predictive data to generate a single, dynamic risk assessment for cancer patients. The algorithm, termed CIRI, outperformed standard methods in predicting patient outcomes and identifying better treatment options.
A study found that a naturally occurring strain of the common cold, coxsackievirus CVA21, can target and destroy bladder cancer cells without causing harm to healthy cells. The treatment showed significant reduction in tumour burden and removal of disease in one patient after just one week.
A new IOF review emphasizes the importance of long-term follow-up to maintain bone health in childhood cancer survivors. The study highlights the need for careful monitoring and management to prevent premature onset of low bone mineral density and improve fracture risk.
A new study shows that niraparib can extend life for women with ovarian cancer who have undergone multiple rounds of chemotherapy. The study found that 27% of patients responded well to the drug and averaged 9.2 months until disease progression, offering hope for a meaningful treatment option.
A new study found that gastric cancer is affecting more young Hispanic people in the US, with poorer outcomes than older patients. Women under 40 were more likely to have diffuse-type tumours and stage IV disease at diagnosis, leading to a median overall survival of just 7 months.
A study by the National Cancer Institute found a clear dose-response relationship between radioactive iodine treatment and long-term risk of death from solid cancers, including breast cancer. The study estimated that for every 1,000 patients treated with standard doses, about 20-30 additional solid cancer deaths would occur.
The foundation awarded Continuation Grants to five Damon Runyon Clinical Investigators, providing an additional two years of funding totaling $400,000. The recipients are conducting patient-oriented cancer research with the goal of finding cures for cancer diagnosis, prevention and treatment.
A 65-year follow-up study of nearly 7,000 Norwegian patients with multiple sclerosis found an overall risk of developing cancer 14% higher than the general population. Respiratory cancer risk was particularly high at 66%, while urinary and central nervous system cancer risks were also significantly increased.
A Danish study of 32,000 haematological cancer patients found that one in five suffer from blood clots or bleeding, with varying risk levels depending on the type of cancer. The research highlights the need for individualized treatment and awareness of high-risk patients to prevent complications.
A new risk prediction model using clinical and radiological features can stratify individuals with lung nodules as having high or low risk of developing lung cancer. The model, which combines variables such as age, smoking history, and nodule characteristics, showed a sensitivity and specificity of 73% and 81%, respectively.
A Penn study shows a Moonshot-funded program can increase cancer patients' engagement in tobacco cessation treatments from 0% to 36%. The program's success is attributed to institutional buy-in and continuous dialogue with clinicians, which informed the development of additional support services.
Researchers sequenced canine cancer cell lines to identify human-like genetic changes driving canine cancers. The study found 61 genetic variants that match known drivers of human cancer, and showed sensitivity to human medicines.
A new systematic review highlights gaps in understanding cancer among LGBTI adolescents and young adults, who face barriers to health services. Researchers propose a Call to Action to reduce these disparities and improve cancer care for this at-risk population.
A national survey finds that half of the population believes cancer requires better treatments, and two-thirds expect most cancers to be curable by 2050. The UK public also supports a tax-funded NHS and wants closer partnerships between the public and private sectors to develop more effective cancer treatments.
A systematic review found that most non-cancerous adrenal tumors do not grow significantly over time, eliminating the need for repeated imaging. Patients with mild cortisol excess may still develop cardiovascular disease, but guidelines should be revised to reflect this low cancer risk and monitor metabolic health instead.
Research found statin therapy significantly reduced stroke risk and overall cardiovascular events in cancer patients who underwent radiation therapy for chest, head, or neck cancer. The study also showed a strong trend toward reduction in cardiovascular deaths.
Researchers at Huntsman Cancer Institute discovered a new experimental drug, selinexor, which may block a crucial survival pathway exploited by myelofibrosis cells. A clinical trial has been designed to examine the drug's effectiveness in patients with myelofibrosis.
Researchers identify barriers to trial accrual, including complexity in staying aware of available trials, identifying eligible patients, and enrolling them. The study suggests addressing these challenges through changes in trial-specific reimbursement and incentives for administrative costs.
A population-based cohort study from 4 Nordic countries found no link between TNFi use and increased cancer risk. However, a significant increase in malignant lymphomas was observed within the trial. Further analysis is needed to determine if this is due to psoriatic arthritis or TNFi treatment.
Researchers developed a biomarker test to predict disease-free survival and recurrence risk in patients with triple-negative breast cancer. The test uses formalin-fixed, paraffin-embedded tissues and has shown promise in predicting patient outcomes.
Researchers found that identifying a patient's Consensus Molecular Subtype (CMS) could help oncologists determine the most effective course of treatment. CMS categorizes colorectal cancer into four distinct subgroups based on tumor mutations, and each subgroup is associated with different treatment outcomes.
Researchers have developed a comprehensive database of synonymous mutations found in cancer, revealing their influence on cellular functions and disease processes. The SynMIC database contains information on 659,194 entries across 88 types of cancer, providing a valuable resource for cancer researchers.
Researchers found HPV16 antibodies develop in body between 6-40 years prior to throat cancer diagnosis, increasing risk significantly. The presence of these antibodies indicates a strong increased risk of disease, particularly among white people, with an estimated 100-fold increase compared to black people.
The seven-year ORATOR trial found no difference in survival between robotic surgery and radiation therapy, but patients receiving radiation experienced better swallowing outcomes. Participants in the surgery group were at risk for complications such as pain, bleeding, and hearing loss.
A nationwide survey of 487 women found that nearly two-thirds of breast cancer patients are unaware of surgical options that can minimize scarring. The study also revealed that many patients experience negative impacts from their scars, including feelings of self-consciousness and restricted clothing choices.
A phase III international clinical trial found that treatment with apalutamide significantly improved overall survival by 33% compared to standard-of-care therapy. The study also showed apalutamide delayed disease progression, increasing the time until chemotherapy was needed.
A recent study found that taking vitamin D for at least three years may lower the risk of death among cancer patients. The researchers analyzed data from over 79,000 patients and discovered a statistically significant difference in mortality rates between those who took vitamin D and those who received a placebo.
A new center will bring together researchers to better understand the relationships between advances in radiation therapy, cancer signaling pathways, and the immune system's ability to control cancer. The center aims to uncover novel insights into cancer biology with potential for more effective treatments.
The study's primary endpoint showed that the total neoadjuvant therapy (TNT) approach was safe, associated with high rates of chemotherapy completion (>90%), but did not demonstrate a significant improvement in reducing cancer presence at surgery. Veliparib addition resulted in more side effects and reduced chemoradiation completion, y...
Researchers developed COXEN, a predictive tool that analyzes gene expression to predict response to chemotherapy in bladder cancer patients. The trial showed COXEN's ability to predict response using Gemcitabine-Cisplatin (GC) biomarker.
A survey of community oncologists found significant knowledge gaps in using genetic testing to decide cancer treatment. Researchers urge immediate education on molecular profiling to direct targeted therapies.
Cancer patients with HIV and viral hepatitis can also reap benefits of immunotherapy, study suggests. These patients respond as well to immune checkpoint inhibitors as those tested in clinical trials.
A survey of 48 oncologists and healthcare providers found that most believe medical marijuana has benefits for cancer patients, but are uncomfortable prescribing it. The main concerns include uncertain dosing, limited knowledge of available products, and potential interactions with other medications.
The latest Annual Report to the Nation on Cancer finds that overall cancer death rates continue to decline in the US. However, a special section reveals a different picture for adults ages 20-49, with higher incidence and mortality among women than men.
A pioneering blood test developed by Johns Hopkins researchers, CancerSEEK, will be developed by Thrive.EarlyDetection Corp. to detect multiple cancer types at earlier stages. The technology has received Breakthrough Device designation from the FDA and has shown high specificity and sensitivity in detecting various cancers.
Sophie Paczesny and her team aim to better understand the tumor microenvironment and identify new checkpoint molecules like ST2. They hope to develop targeted therapies using antibodies that can boost the immune system's ability to attack cancer cells.
A new blood test, DELFI, uses machine learning to identify abnormal DNA patterns in the bloodstream for early cancer detection. The test detected cancer DNA in 57-99% of patients with various stages of breast, colorectal, and other cancers.
A new urology care model developed by Flinders University focuses on supporting bladder cancer patients' partners and family, addressing their daily impacts and needs. Health professionals can capitalize on this by providing clear information, counseling, and support to manage the shock, fear, and treatment of bladder cancer.
A large-scale analysis of over 3,000 patients with early oesophagus and stomach cancer found that female patients are more likely to survive longer than male patients, but experience more severe gastrointestinal side effects during chemotherapy. Researchers hope the findings can help tailor treatment approaches for individual patients.
A new study found that one-third of patients with metastatic pancreatic cancer do not see a medical oncologist, and even more do not receive cancer-directed treatment. The data suggest that there are many missed opportunities for important discussions between patients and cancer specialists.
Researchers from QUT and Edith Cowan University published new exercise guidelines that recommend a personalized approach to exercise prescription. The guidelines suggest moderate to high intensity exercise, but emphasize the importance of tailoring the program to individual patient needs and priorities.
Researchers found that proton therapy significantly lowers the risk of severe side effects in cancer patients undergoing radiation and chemotherapy, with a relative risk reduction of two-thirds. Cure rates were almost identical between groups.
Incidence rates of uterine cancer's aggressive subtypes increased dramatically among all racial groups from 2000 to 2015, with black women having higher rates and poorer survival. Endometrioid subtypes showed stable trends in white women but increasing rates in other groups.
Researchers at Medical University of South Carolina identified a metabolic Achilles heel in cancer, exploiting glutamine addiction. A new combination treatment has shown promise in treating drug-resistant esophageal cancer cells.
A team of researchers at Medical University of South Carolina developed a natural language processing software that identified socially isolated prostate cancer patients with 90 percent accuracy. This technology can help physicians provide care informed by an awareness of their patients' social determinants of health, including social ...
The Case Comprehensive Cancer Center has been selected as a Lead Academic Participating Site by the National Cancer Institute for a six-year grant worth $8.9 million. This renewal grant enables the center to provide patients with additional access to clinical trials through the National Clinical Trials Network.